Last reviewed · How we verify
Prevention of opioid abuse
Approved treatments
- Subutex · Indivior
Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors. - Narcan · Adapt
- Naltrexon · Institute of Liver and Biliary Sciences, India
- Subutex · Purdue Pharma Lp
Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of opioid abuse patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of opioid abuse treatment landscape brief
- Prevention of opioid abuse treatment updates RSS
Frequently asked questions about Prevention of opioid abuse
What drugs treat Prevention of opioid abuse?
Tracked treatments include Subutex, Narcan, Naltrexon.
What is the treatment for Prevention of opioid abuse?
Standard treatment for Prevention of opioid abuse includes Subutex, Narcan, Naltrexon. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of opioid abuse patent cliff · Prevention of opioid abuse CI report
- Treatment: Subutex · Indivior
- Treatment: Narcan · Adapt
- Treatment: Naltrexon · Institute of Liver and Biliary Sciences, India
- Treatment: Subutex · Purdue Pharma Lp
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing